{"entity":{"id":"omniseq-insight","kind":"drug","name":"OmniSeq INSIGHT","aka":["Labcorp OmniSeq INSIGHT","OmniSeq INSIGHT Genomic Profiling Assay"],"tldr":"Labcorp's tissue gene test for solid tumours, covering 523 genes with a 7 to 10 day turnaround and an option to add PD-L1 testing on the same sample.","summary":"OmniSeq INSIGHT is Labcorp's tissue comprehensive genomic profiling test for solid tumours, with a stated turnaround of 7 to 10 days. It reads the full coding sequence of 523 cancer-related genes for single-nucleotide variants, insertions and deletions, amplifications and translocations, and RNA from 55 genes for fusions and splice variants, and it reports microsatellite instability and tumour mutational burden; Labcorp's assay specifications list homologous recombination deficiency reporting as an option. It can be combined with PD-L1 testing on the same tissue. The clinical test is a laboratory-developed test; Labcorp also offers the assay to drug developers for research and investigational use, and a plasma version, OmniSeq INSIGHT ctDNA, for research use only.","status":"established","asOf":"2026-11-03","links":[{"label":"Labcorp Oncology: solid tumour testing (OmniSeq INSIGHT)","url":"https://www.labcorp.com/oncology/providers/testing-solutions/solid-tumor"},{"label":"Labcorp: OmniSeq INSIGHT Genomic Profiling assay specifications","url":"https://www.labcorp.com/oncology/biopharma/portfolio/solid-tissue-profiling/omniseq-insight-genomic"}],"tags":["test"],"related":["pd-l1-cps","pd-l1-tps","msi-high","tmb-high"],"cancers":["metastatic-cancer"],"sections":[],"technologies":["cgp","reference-laboratories"],"targets":[],"drugs":[],"companies":["labcorp"],"institutions":[],"pathways":[],"terms":["ngs","tmb","msi","hrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: an alteration linked to an approved drug or a trial is listed with it; a sample with too little tumour can fail, which is not a negative result."],"brand":"OmniSeq INSIGHT","modality":"Tissue comprehensive genomic profiling test (DNA and RNA sequencing)","mechanism":"Sequencing of the full coding sequence of 523 cancer-related genes in tumour DNA, and of 55 genes in tumour RNA for fusions and splice variants, from formalin-fixed tissue.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/omniseq-insight/","neighbours":{"biomarker":[{"id":"msi-high","kind":"biomarker","name":"MSI-high (microsatellite instability by PCR or sequencing)","route":"/biomarkers/msi-high/"},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/"},{"id":"pd-l1-tps","kind":"biomarker","name":"PD-L1 TPS (tumour proportion score)","route":"/biomarkers/pd-l1-tps/"},{"id":"tmb-high","kind":"biomarker","name":"TMB-high (tumour mutational burden >= 10 mutations per megabase)","route":"/biomarkers/tmb-high/"}],"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"reference-laboratories","kind":"technology","name":"Reference laboratories and companion-diagnostic testing","route":"/technologies/reference-laboratories/"}],"company":[{"id":"labcorp","kind":"company","name":"Labcorp","route":"/companies/labcorp/"}],"term":[{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/"},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}]}}